Viriom, Inc. (Viriom) announced today the initiation of a Phase 2a study investigating the efficacy of an intramuscular long-acting injectable nanoformulation of VM1500A in HIV-infected patients. The earlier findings of a Phase 1 study investigating safety and pharmacokinetics with single and multiple dosing of this formulation were presented at CROI 2020 in Boston.
Viriom Launches Reproductive Toxicity Studies for Elpida® (Elsulfavirine) Once Weekly Oral Formulation
SAN DIEGO, Dec. 3, 2019 -- Viriom Inc (Viriom) announces launching Segment I and Segment II reproductive toxicity studies of Elpida® (elsulfavirine) HIV-1 therapy, supported by preclinical services of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Viriom Wins Grant Award To Establish Affiliate In Mainland China
Viriom Inc. (San Diego, CA), has won a grant award in the city of Shaoxing, Zhejiang province, to establish its affiliate in Mainland China. Viriom opened a representative office in Beijing in 2017 and is establishing an affiliate in Hong Kong as part of its five-year plan of drug development and technology transfer to attend to markets, including Greater China, Thailand and Indonesia, where over 5 million people live with an HIV infection.